Cipla’s Q1FY25 Quarter Results
Cipla’s revenue grew 6% YoY
- 29 Jul 2024
- Cipla reported a 7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter ended June (Q1FY25). On a year-on-year (YoY) basis, it witnessed a growth of 6%.
- Its expenses for the quarter were up by 2% QoQ and 3% YoY.
- The net profit grew 26% QoQ and 17.8% YoY.
- The earnings per share (EPS) of Cipla stood at 14.6 during Q1FY25.
Cipla’s Financial Statements for Q1FY25:
| (Rs crores) | Q1FY24 | Q4FY24 | Q1FY25 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total income | 6,465 | 6,413 | 6,854 | 7% | 6.0% |
Total expenses | 5,091 | 5,153 | 5,243 | 2% | 3.0% |
Profit before tax | 1,375 | 1,259 | 1,611 | 28% | 17.2% |
Tax | 378 | 325 | 435 | 34% | 15.1% |
Profit after tax | 998 | 932 | 1,175 | 26% | 17.8% |
Earnings per share | 12.3 | 11.6 | 14.6 |
Financials:
- Net Profit: Reported a 17.8% year-on-year (Y-o-Y) and 26% increase in net profit.
- PAT: Profit after tax (PAT) for Q1FY25 stood at ₹1,175 crores.
- Revenue from Operations: Total revenue from operations reached ₹6,694 crores, an increase of 7% Y-o-Y.
- EBITDA: ₹1,716 Cr 14% year-on-year (YoY) growth, with an operating margin of 25.6%.
Management Commentary:
Mr. Umang Vohra, MD and Global CEO of Cipla Ltd, said,
- "I am pleased to share that we continue to make considerable progress across our focused markets. In Q1 FY25, we recorded revenue growth of 7% over last year with EBITDA margin of 25.6% driven by mix and other operational efficiencies.
- Our One-India business continued on its growth trajectory during the quarter, led by Branded Prescription that grew at 10%.
- Our concentrated focus and execution in differentiated portfolio have further strengthened the US business that yet again posted an all-time high quarterly revenue at $250 million. In South Africa, we recorded a solid growth of 19% YoY in local currency terms, led by the private market.
- Going ahead, focus will be on growing our key markets, further building our flagship brands, investing in future pipelines as well as focusing on resolutions on the regulatory front."
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Open Demat Account
